Publications & Presentations
Prof Vela has given 35 national and international invited presentations in the last 5 years. He has spoken at multiple community engagement events including PCFA Community Conversations, PCFA support groups, Men’s Shed nights, and the QBCI Consumer Forum as part of the bladder cancer initiative that leads. In 2019 he co-led a delegation to Canberra for a “Bladder Cancer: Let’s start the conversation” event with the Parliamentary Friends of Cancer Causes.
Joshi, A., Roberts, M.J., Perera, M, ...... and Vela, I [2020] The clinical efficacy of PSMA PET/MRI in biochemically recurrent prostate cancer compared with standard of care imaging modalities and confirmatory histopathology: results of a single-centre, prospective clinical trial. Clin Exp Metastasis. https://doi.org/10.1007/s10585-020-10043-1
Joshi, A., Roberts, M.J., Alinezhad, S., Williams, E.D. and Vela, I. [2020], Challenges, applications and future directions of precision medicine in prostate cancer – the role of organoids and patient‐derived xenografts. BJU Int. doi:10.1111/bju.15103
Gordon L, Elliott T, Joshi A, Williams E, Vela I, [2020] Exploratory cost-effectiveness analysis of 68Gallium-PSMA PET/MRI-based imaging in patients with biochemical recurrence of prostate cancer, Clinical and Experimental Metastasis, 37 (2), p305-312
Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, Christidis D, Bolton D, Hofman M, Lawrentschuk N, Murphy D, [2020] Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancerupdated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions, European Urology, 77 (4), p403-417
Hofman M, Lawrentschuk N, Francis R, Tang C, Vela I, Thomas P, Rutherford N, Martin J, Frydenberg M, Shakher R, Wong L, Taubman K, Ting Lee S, Hsiao E, Roach P, Nottage M, Kirkwood I, Hayne D, Link E, Marusic P, ..... , [2020] Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): A prospective, randomised, multi-centre study, The Lancet, 395 (10231), p1208-1216
De Bruycker A, Tran P, Achtman A, Ost P, Boutros P, Buzza M, Corcoran N, Dal Pra A, Emmenegger U, Fraser M, Hovens C, Koontz B, Lapointe J, Vela I, , [2020] Clinical perspectives from ongoing trials in oligometastatic or oligorecurrent prostate cancer, World Journal of Urology, p1-10
Roberts M, Papa N, Perera M, Scott S, Teloken P, Joshi A, Vela I, Pryor D, Martin J, Woo H, [2019] A contemporary, nationwide analysis of surgery and radiotherapy treatment for prostate cancer, BJU International, 124 (S1), p31-36
Tariq A, Khan S, Vela I, Williams E, [2019] Assessment of the use of the Internet and social media among people with bladder cancer and their carers, and the quality of available patient-centric online resources, BJU International, 123 (S5), p10-18
Pereira R, McGeorge S, Perera M, Vela I, [2019] Urachal mucinous cystadenocarcinoma, BMJ Case Reports, 12 (1), p1-4
Ahn T, Roberts M, Abduljabar A, Joshi A, Perera M, Rhee H, Wood S, Vela I, [2019] A review of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in Renal Cell Carcinoma (RCC), Molecular Imaging and Biology, 21 (5), p799-807
Pereira R, Joshi A, Roberts M, Yaxley J, Vela I, [2019] Open retropubic radical prostatectomy, Translational Andrology and Urology, p1-11
Kulasinghe A, Kapeleris J, Kenny L, Warkiani M, Vela I, Thiery J, O'Byrne K, Punyadeera C, [2019] Isolation, characterization and expansion of circulating tumor cells in solid cancers, Cancer Research, 79 (13 Supp)
Kapeleris J, Kulasinghe A, Ebrahimi Warkiani M, Vela I, Kenny L, O'Byrne K, Punyadeera C, [2018] The prognostic role of circulating tumor cells (CTCs) in lung cancer, Frontiers in Oncology, 8, p1-13
Kulasinghe A, Perry C, Kenny L, Blick T, Warkiani M, Vela I, O'byrne K, Thiery J, Thompson E, Nelson C, Punyadeera C, [2018] Circulating tumor cells: The tumor trail left in the blood, Cancer Research, 78 (13S)
Saadat S, Tie B, Wood S, Vela I, Rhee H, [2018] Imaging tumour thrombus of clear cell renal cell carcinoma: FDG PET or PSMA PET? Direct in vivo comparison of two technologies, Urology Case Reports, 16, p4-5
Nicholson C, Vela I, Williams E, [2017] Prostate cancer metastasis. In AAhmad, Introduction to cancer metastasis (Cancer metastasis, Volume 1), Academic Press, p33-59
Kothari G, Louie A, Pryor D, Vela I, Lo S, Teh B, Siva S, [2017] Stereotactic body radiotherapy for primary renal cell carcinoma and adrenal metastases, Chinese Clinical Oncology, 6 (S2), p1-15
Gunter J, Rhee H, Sarkar P, Lee W, Philp L, Hollier B, Williams E, Vela I, Sadowski M, Lehman M, Nelson C, [2017] Targeting metabolic dysfunction induced by ADT in advance prostate cancer, Asia-Pacific Journal of Clinical Oncology, 13 (S1), p30-30
Joshi A, Nicholson C, Rhee H, Gustafson S, Miles K, Vela I, [2017] Incidental malignancies identified during staging for prostate cancer with 68Ga prostate-specific membrane antigen HBED-CC positron emission tomography imaging, Urology, 104, pe3-e4
Sternberg I, Vela I, Scardino P, [2016] Molecular profiles of prostate cancer: To treat or not to treat, Annual Review of Medicine, 67, p119-135
Rhee H, Blazak J, Tham C, Lim Ng K, Shepherd B, Lawson M, Preston J, Vela I, Thomas P, Wood S, [2016] Pilot study: use of gallium-68 PSMA PET for detection of metastatic lesions in patients with renal tumour, EJNMMI Research, 6, p1-6
Teleni L, Chan R, Chan A, Isenring E, Vela I, Inder W, McCarthy A, [2016] Exercise improves quality of life in androgen deprivation therapy-treated prostate cancer: systematic review of randomised controlled trials, Endocrine-Related Cancer, 23 (2), p101-112
Rhee H, Vela I, Chung E, [2016] Metabolic syndrome and prostate cancer: A review of complex interplay amongst various endocrine factors in the pathophysiology and progression of prostate cancer, Hormones and Cancer, 7 (2), p75-83
Rhee H, Thomas P, Shepherd B, Gustafson S, Vela I, Russell P, Nelson C, Chung E, Wood G, Malone G, Wood S, Heathcote P, [2016] Prostate specific membrane antigen positron emission tomography may improve the diagnostic accuracy of multiparametric magnetic resonance imaging in localized prostate cancer, Journal of Urology, 196 (4), p1261-1267
Tang K, Liu J, Jovanovic L, An J, Hill M, Vela I, Lee T, Ma S, Nelson C, Russell P, Clements J, Ling P, [2016] Adipocytes promote prostate cancer stem cell self-renewal through amplification of the cholecystokinin autocrine loop, OncoTarget, 7 (4), p4939-4948
Kulasinghe A, Kenny L, Perry C, Thiery J, Jovanovic L, Vela I, Nelson C, Punyadeera C, [2016] Impact of label-free technologies in head and neck cancer circulating tumour cells, OncoTarget, 7 (44), p71223-71234
Kulasinghe A, Perry C, Ebrahimi Warkiani M, Blick T, Davies A, O'Byrne K, Thompson R, Nelson C, Vela I, Punyadeera C, [2016] Short term ex-vivo expansion of circulating head and neck tumour cells, OncoTarget, 7 (37), p60101-60109
McGrath S, Christidis D, Perera M, Hong S, Manning T, Vela I, Lawrentschuk N, [2016] Prostate cancer biomarkers: Are we hitting the mark?, Prostate International, 4 (4), p130-135
Rhee H, Lim Ng K, Tse B, Yeh M, Russell P, Nelson C, Thomas P, Samaratunga H, Vela I, Gobe G, Wood S, [2016] Using prostate specific membrane antigen (PSMA) expression in clear cell renal cell carcinoma for imaging advanced disease [Correspondence], Pathology, 48 (6), p613-616
Vela I, Chen Y, [2015] Prostate cancer organoids: a potential new tool for testing drug sensitivity [Editorial], Expert Review of Anticancer Therapy, 15 (3), p261-263
Gao D, Vela I, Sboner A, Iaquinta P, Karthaus W, [2014] Organoid cultures derived from patients with advanced prostate cancer, Cell, 159 (1), p176-187
Vela I, Morrissey C, Zhang X, Chen S, Corey E, Strutton G, Nelson C, Nicol D, Clements J, Gardiner E, [2014] PITX2 and non-canonical Wnt pathway interaction in metastatic prostate cancer, Clinical and Experimental Metastasis, 31 (2), p199-211
Laudone, V, Vela I,[2014] Editorial Comment re: Minimally Invasive Cystectomy is Associated with Improved Perioperative Patient Safety Outcomes Compared to Open Cystectomy in a National Cohort" Urology, Volume 84, Issue 2, Pages 319-319
Vela I, et al. [2014] PITX2 and non-canonical Wnt pathway interaction in metastatic prostate cancer. Clin Exp Metastasis. Feb;31(2):199-211
Laudone, V, Vela I, [2013] Editorial Comment re: "Complications Associated with Extraperitoneal Robot Assisted Radical Prostatectomy using the Standardized Martin Classification." Urology. Feb, 81, (2): 331-332
Vela, I et al. [2010]. “PITX2: a potential new target in metastatic prostate cancer”. AUA News Vol 15 issue 10
Vela, I., et al. [2007]. "Bone and prostate cancer cell interactions in metastatic prostate cancer." BJUI 99(4): 735-742.
Awards
Jan 2020
STEPS Program EAU Section of Oncological Urology (EOUS) Dublin
1 of 20 international urologists selected and first Australian
May 2017
Best of Best Plenary Podium - “Novel in vitro organoid technology to facilitate a precision medicine approach in the management of men with biochemical recurrence of prostate cancer”
Annual Scientific Meeting of the American Urologic Association, Boston, Massachusetts, USA
Sep 2011
USANZ Trainee Representative to European Urology Residents Education Programme (EUREP) Meeting in Prague, Czech Republic.
Apr 2018
USANZ Lecturer – “Precision Medicine in Localised and Early Recurrent Prostate Cancer”
Urological Association of Asia 2018 Annual Scientific Meeting, Kyoto, Japan.
May 2017
BJUI Sponsored USANZ lecture – “Personalised Medicine for Prostate Cancer”
BAUS-BJUI-USANZ Joint Session of the Annual Scientific Meeting of the American Urologic Association, Boston, Massachusetts, USA
Nov 2015
Visiting Professor
National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
May 2010
Best Poster: Prostate Cancer Basic Research IV
Annual Scientific Meeting of the American Urologic Association
May 2017
Winner 2017 ASMR Queensland Health & Medical Research Awards-Clinician Researcher Category
May 2017
PCFA Community Conversations
Brisbane, QLD, Australia
Nov 2015
Visiting Professor
Walter Reed National Military Medical Center, Bethesda, Maryland, USA
Apr 2015
Abbvie Platinum Trophy Winner
USANZ
October 2009
Winner, Neville Davis Research Prize
Royal Australasian College of Surgeons
Associations
2018 – present Uro-oncology Special Advisory Group (SAG) USANZ — Member
2017 – present The Australian Society for Medical Research (ASMR) — Member
2017 – present Scientific Advisory Board Healthy Male — Member
2017 – present Academy of Surgical Educators, (RACS) — Member
2016 – present Translational Research Sub-committee ANZUP — Member
2016 – present Prostate Cancer Sub-committee ANZUP — Member
2015 – present European Association of Urology (EAU) — International Member
2014 – present Institute of Health and Biomedical Innovation (IHBI), Queensland University of Technology (QUT) — Member
2014 – present Australian Prostate Research Center - QLD (APCRC-Q) — Member
2014 – present Translational Research Institute (TRI) — Member
2012 – present Society of Urologic Oncology (SUO) — International Member
2012 – present American Urological Association (AUA) — International Member
2012 – present The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) — Member
2012 – present Urological Society of Australia and New Zealand (USANZ) — Member
2012 – present Royal Australasian College of Surgeons (RACS) — Fellow
Prof Vela also sits on multiple medical advisory boards for various industry bodies and multiple grant review committees for various national and international funding bodies, as well as being an invited reviewer for ten international journals.